Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$913K Hold
3,626
0.43% 32
2026
Q1
$789K Hold
3,626
0.44% 30
2025
Q4
$829K Hold
3,626
0.46% 28
2025
Q3
$840K Buy
3,626
+173
+5% +$35.2K 0.53% 26
2025
Q2
$641K Sell
3,453
-507
-13% -$94.2K 0.45% 37
2025
Q1
$830K Hold
3,960
0.69% 26
2024
Q4
$704K Hold
3,960
0.51% 32
2024
Q3
$782K Hold
3,960
0.57% 31
2024
Q2
$679K Sell
3,960
-118
-3% -$19.5K 0.53% 32
2024
Q1
$743K Buy
4,078
+206
+5% +$35.5K 0.62% 29
2023
Q4
$600K Buy
+3,872
New +$565K 0.54% 34

Other funds holding ABBV

Gerber LLC's ABBV Position: Q2 2026 in Review

Gerber LLC held its AbbVie (ABBV) position steady in Q2 2026 at 3,626 shares worth $913K. The position accounts for 0.43% of the portfolio, ranked #32.

Gerber LLC first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 2,345 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Gerber LLC held 3,626 shares of AbbVie worth $913K as of Q2 2026.
  • Gerber LLC left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.43% of Gerber LLC's portfolio in Q2 2026, its #32 holding.
  • Gerber LLC first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 2,345 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Gerber LLC's 13F filing for Q2 2026, filed 29 Jul 2026.